Pitlovanciv Tatiane Elen de Souza, Skare Thelma Larocca, Medeiros Karina Bittencourt, Fabri Andréa Buosi
Department of Clinical Medicine, Federal University of Paraná, Curitiba, Brazil.
Department of Clinical Medicine, Mackenzie Evangelical University Hospital, Curitiba, Brazil.
Skin Appendage Disord. 2025 Apr;11(2):151-158. doi: 10.1159/000540846. Epub 2024 Sep 10.
Topical and systemic drugs, as methotrexate (MTX), do not control the frontal fibrosing alopecia (FFA) activity in most of the cases showing the need for new therapies. Therefore, we aimed to evaluate the effectiveness of MTX microinfusion in FFA.
Prospective, controlled clinical trial, carried out with 17 volunteers with clinical and histological diagnosis of FFA. Applications of MTX by MMP (microinfusion of drugs into the skin method) were made every 30 days, in a total of 03 applications, in the right half of the alopecia area; the other half served as a control.
There was a significant reduction in frontal-glabella and frontal temporoparietal measurements at treated site while in the untreated site the FFA increased. Patient's referred improvement of pruritus and desquamation but not in hair loss and local erythema. Analysis of the dermoscopic photos and the LPPAI calculation did not show relevant changes. About 95% of the participants were satisfied or very satisfied with the results and none of them had alteration in the laboratory test results.
The MTX application by MMP improved symptoms associated with FFA, and the frontal-glabella and frontal temporoparietal measurements. This technique proved to be safe and well tolerated.
局部和全身用药，如甲氨蝶呤（MTX），在大多数病例中无法控制额部纤维性脱发（FFA）的病情活动，这表明需要新的治疗方法。因此，我们旨在评估MTX微注射治疗FFA的有效性。
对17名临床和组织学诊断为FFA的志愿者进行前瞻性对照临床试验。采用MMP（药物微注射入皮法）每30天在脱发区域的右半部分注射一次MTX，共注射3次；另一半作为对照。
治疗部位的额部-眉间和额颞顶测量值显著降低，而未治疗部位的FFA增加。患者称瘙痒和脱屑有所改善，但脱发和局部红斑没有改善。皮肤镜照片分析和LPPAI计算未显示相关变化。约95%的参与者对结果满意或非常满意，且他们的实验室检查结果均无改变。
通过MMP应用MTX可改善与FFA相关的症状以及额部-眉间和额颞顶测量值。该技术被证明是安全且耐受性良好的。
